229 related articles for article (PubMed ID: 32569821)
1. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
3. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Lubitz CC; Sadow PM; Daniels GH; Wirth LJ
Thyroid; 2021 Oct; 31(10):1451-1462. PubMed ID: 33860688
[No Abstract] [Full Text] [Related]
4. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
6. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
7. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
8. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
9. Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.
Němčíková P; Brunerová L
Vnitr Lek; 2023; 69(5):312-315. PubMed ID: 37827829
[TBL] [Abstract][Full Text] [Related]
10. Cytologic features of aggressive variants of follicular-derived thyroid carcinoma.
Rossi ED; Faquin WC; Pantanowitz L
Cancer Cytopathol; 2019 Jul; 127(7):432-446. PubMed ID: 31150164
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.
Xu B; Ghossein R
Eur J Surg Oncol; 2018 Mar; 44(3):338-347. PubMed ID: 28554832
[TBL] [Abstract][Full Text] [Related]
12. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
13. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects.
Puliafito I; Esposito F; Prestifilippo A; Marchisotta S; Sciacca D; Vitale MP; Giuffrida D
Front Endocrinol (Lausanne); 2022; 13():860671. PubMed ID: 35872981
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
[TBL] [Abstract][Full Text] [Related]
15. Interplay of fibroblasts with anaplastic tumor cells promotes follicular thyroid cancer progression.
Fozzatti L; Alamino VA; Park S; Giusiano L; Volpini X; Zhao L; Stempin CC; Donadio AC; Cheng SY; Pellizas CG
Sci Rep; 2019 May; 9(1):8028. PubMed ID: 31142771
[TBL] [Abstract][Full Text] [Related]
16. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
17. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
18. Well-differentiated carcinoma of the thyroid.
Boone RT; Fan CY; Hanna EY
Otolaryngol Clin North Am; 2003 Feb; 36(1):73-90, viii. PubMed ID: 12803010
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract][Full Text] [Related]
20. Follicular and Hürthle cell lesions of the thyroid: can inconclusive results be minimized?
Sherman JF; Leiman G; Naud S; Nathan MH; Ambaye AB
Acta Cytol; 2008; 52(6):659-64. PubMed ID: 19068668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
